Insulin resistance, steatosis and hepatitis C virus

Alessandra Mangia, Maria Ripoli

Research output: Contribution to journalArticle

Abstract

Epidemiological studies have shown an increased occurrence of metabolic disorders such as insulin resistance (IR) and steatosis in patients with hepatitis C virus (HCV) infection. IR is believed to represent one of the central clinical features of the "metabolic syndrome" and the major pathogenetic factor for type 2 diabetes mellitus. In patients with chronic HCV hepatitis, IR may have several dangerous consequences such as accelerated progression of liver fibrosis, resistance to antiviral therapy and development of hepatocellular carcinoma. According to recent evidence, the global epidemic of metabolic disorders related to incorrect diets will lead physicians to deal with 1.2 billion patients with diabetes in the world in 2025. Given the high prevalence of HCV infection in several countries, metabolic manifestations will contribute to increasing morbidity and mortality in patients with HCV chronic infection in the near future. HCV treatment, shown able to decrease both the occurrence of HCV-related IR and diabetes, may reduce the risk of the associated morbidities.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalHepatology International
DOIs
Publication statusAccepted/In press - 2013

Fingerprint

Hepacivirus
Insulin Resistance
Virus Diseases
Morbidity
Chronic Hepatitis C
Liver Cirrhosis
Type 2 Diabetes Mellitus
Hepatitis
Antiviral Agents
Epidemiologic Studies
Hepatocellular Carcinoma
Diet
Physicians
Mortality
Therapeutics

Keywords

  • Chronic hepatitis C
  • Insulin resistance
  • Pegylated interferon
  • Ribavirin
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Hepatology

Cite this

Insulin resistance, steatosis and hepatitis C virus. / Mangia, Alessandra; Ripoli, Maria.

In: Hepatology International, 2013, p. 1-8.

Research output: Contribution to journalArticle

@article{6dacb06f35714878a80e9490909078e0,
title = "Insulin resistance, steatosis and hepatitis C virus",
abstract = "Epidemiological studies have shown an increased occurrence of metabolic disorders such as insulin resistance (IR) and steatosis in patients with hepatitis C virus (HCV) infection. IR is believed to represent one of the central clinical features of the {"}metabolic syndrome{"} and the major pathogenetic factor for type 2 diabetes mellitus. In patients with chronic HCV hepatitis, IR may have several dangerous consequences such as accelerated progression of liver fibrosis, resistance to antiviral therapy and development of hepatocellular carcinoma. According to recent evidence, the global epidemic of metabolic disorders related to incorrect diets will lead physicians to deal with 1.2 billion patients with diabetes in the world in 2025. Given the high prevalence of HCV infection in several countries, metabolic manifestations will contribute to increasing morbidity and mortality in patients with HCV chronic infection in the near future. HCV treatment, shown able to decrease both the occurrence of HCV-related IR and diabetes, may reduce the risk of the associated morbidities.",
keywords = "Chronic hepatitis C, Insulin resistance, Pegylated interferon, Ribavirin, Type 2 diabetes mellitus",
author = "Alessandra Mangia and Maria Ripoli",
year = "2013",
doi = "10.1007/s12072-013-9460-1",
language = "English",
pages = "1--8",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",

}

TY - JOUR

T1 - Insulin resistance, steatosis and hepatitis C virus

AU - Mangia, Alessandra

AU - Ripoli, Maria

PY - 2013

Y1 - 2013

N2 - Epidemiological studies have shown an increased occurrence of metabolic disorders such as insulin resistance (IR) and steatosis in patients with hepatitis C virus (HCV) infection. IR is believed to represent one of the central clinical features of the "metabolic syndrome" and the major pathogenetic factor for type 2 diabetes mellitus. In patients with chronic HCV hepatitis, IR may have several dangerous consequences such as accelerated progression of liver fibrosis, resistance to antiviral therapy and development of hepatocellular carcinoma. According to recent evidence, the global epidemic of metabolic disorders related to incorrect diets will lead physicians to deal with 1.2 billion patients with diabetes in the world in 2025. Given the high prevalence of HCV infection in several countries, metabolic manifestations will contribute to increasing morbidity and mortality in patients with HCV chronic infection in the near future. HCV treatment, shown able to decrease both the occurrence of HCV-related IR and diabetes, may reduce the risk of the associated morbidities.

AB - Epidemiological studies have shown an increased occurrence of metabolic disorders such as insulin resistance (IR) and steatosis in patients with hepatitis C virus (HCV) infection. IR is believed to represent one of the central clinical features of the "metabolic syndrome" and the major pathogenetic factor for type 2 diabetes mellitus. In patients with chronic HCV hepatitis, IR may have several dangerous consequences such as accelerated progression of liver fibrosis, resistance to antiviral therapy and development of hepatocellular carcinoma. According to recent evidence, the global epidemic of metabolic disorders related to incorrect diets will lead physicians to deal with 1.2 billion patients with diabetes in the world in 2025. Given the high prevalence of HCV infection in several countries, metabolic manifestations will contribute to increasing morbidity and mortality in patients with HCV chronic infection in the near future. HCV treatment, shown able to decrease both the occurrence of HCV-related IR and diabetes, may reduce the risk of the associated morbidities.

KW - Chronic hepatitis C

KW - Insulin resistance

KW - Pegylated interferon

KW - Ribavirin

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84882543035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882543035&partnerID=8YFLogxK

U2 - 10.1007/s12072-013-9460-1

DO - 10.1007/s12072-013-9460-1

M3 - Article

SP - 1

EP - 8

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

ER -